Mass treatment of onchocerciasis with ivermectin: Should people with epilepsy and/or growth-retardation syndromes be excluded?

Annals of Tropical Medicine and Parasitology

Volumn 98, Issue 2, 2004, Pages 99-114

  Twum Danso, N A Y ^a  

^a Mectizan Donation Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ANTICONVULSIVE AGENT; GLYCOPROTEIN P; IVERMECTIN;

AFRICA; BLOOD BRAIN BARRIER; BRAIN TOXICITY; CHRONIC WASTING DISEASE; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG TRANSPORT; ENDEMIC DISEASE; EPILEPSY; GROWTH RETARDATION; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; MEDICAL LITERATURE; NONHUMAN; ONCHOCERCIASIS; PREVALENCE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR;

AFRICA; ANIMALS; ANTHELMINTICS; DEVELOPING COUNTRIES; ENDEMIC DISEASES; EPILEPSY; GROWTH DISORDERS; HUMANS; INCIDENCE; IVERMECTIN; ONCHOCERCIASIS; PREVALENCE;

NEMATODA;

EID: 1642371221     PISSN: 00034983     EISSN: None     Source Type: Journal    
DOI: 10.1179/000349804225003208     Document Type: Review

References (69)

1. Adamolekun, B. (1995). The aetiologies of epilepsy in tropical Africa. Tropical and Geographic Medicine, 47, 115-117.
2. Ammendola, D., de Sarro, A., de Sarro, G. B., Germanà, G., Naccari, F. & Rotiroti, D. (1988). Anticonvulsant effects of avermectin in DBA/2 mice and rat. Experimental Biology, 48, 13-17.
3. Anon. (1994). Relationship between epilepsy and tropical diseases. Epilepsia, 35, 89-93.
4. Anon. (1998). Community-based Mass Treatment of Onchocerciasis: Program Information. Decatur, GA: Mectizan Donation Program.
5. Anon. (2001). Summary of Product Characteristics No. 472/1197 MCT PO 003 SPC CUR 03.12.01. Whitehouse Station, NJ: Merck & Co.
6. Attia-Romdhane, N., Mrabet, A. & Ben Hamida, M. (1993). Prevalence of epilepsy in Kelibia, Tunisia. Epilepsia, 34, 1028-1032.
7. Bagenda, R., Batwala, J. & Stanfield, J. P. (1964). Banakalanga: a domiciliary study into definitions and attitudes. East African Medical Journal, 41, 324-332.
8. Bondestam, S., Garssen, J. & Abdulwakil, A. I. (1990). Prevalence and treatment of mental disorders and epilepsy in Zanzibar. Acta Psychiatrica Scandinavica, 81, 327-331.
9. Boussinesq, M., Pion, S. D. S., Demanga-Ngangue & Kamgno, J. (2002). Relationship between onchocerciasis and epilepsy: a matched case-control study in the Mbam Valley, Republic of Cameroon. Transactions of the Royal Society of Tropical Medicine and Hygiene, 96, 537-541.
10. Burnham, G. (1993). Adverse reactions to ivermectin treatment for onchocerciasis. Results of a placebo-controlled, double-blind trial in Malawi. Transactions of the Royal Society of Tropical Medicine and Hygiene, 87, 313-317.
11. Campbell, W. C., Fisher, M. H., Stapley, E. O., Albers-Schönberg, G. & Jacob, T. A. (1983). Ivermectin: a potent new antiparasitic agent. Science, 221, 823-828.
12. Collomb, H., Dumas, M., Ayats, H., Virieu, R., Simon, M. & Roger, J. (1970). Epidémiologie de l'épilepsie au Sénégal. African Journal of Medical Sciences, 1, 125-148.
13. Crichlow, E. C., Mishra, P. R. & Crawford, R. D. (1986). Anticonvulsant effects of ivermectin in genetically-epileptic chickens. Neuropharmacology, 25, 1085-1088.
14. De Bittencourt, P. R. M., Adamolekum, B., Bharucha, N., Carpio, A., Cossio, H., Danesi, M. A., Dumas, M., Meinardi, H., Ordinario, A., Senanayake, N., Shakir, R. & Sotelo, J. (1996). Epilepsy in the tropics. I. Epidemiology, socioeconomic risk factors, and etiology. Epilepsia, 37, 1121-1127.
15. Druet-Cabanac, M., Preux, P. M., Bouteille, B., Bernet-Bernady, P., Dunand, J., Hopkins, A., Yaya, G., Tabo, A., Sartoris, C., Macharia, W. & Dumas, M. (1999). Onchocerciasis and epilepsy: a matched case-control study in the Central African Republic. American Journal of Epidemiology, 149, 565-570.
16. Duke, B. O. L. (1998). Onchocerciasis, epilepsy and hyposexual dwarfism. Transactions of the Royal Society of Tropical Medicine and Hygiene, 92, 236.
17. Duke, B. O. L., Vincelette, J. & Moore, P. J. (1976). Microfilariae in the cerebrospinal fluid, and neurologic complications, during treatment of onchocerciasis with diethylcarbamazine. Tropenmedizin und Parasitologie, 27, 123-132.
18. Etter, A., Cully, D. F., Liu, K. K., Reiss, B., Vassilatis, D. K., Schaeffer, J. M. & Arena, J. P. (1999). Picrotoxin blockage of invertebrate glutamate-gated chloride channels: subunit dependence and evidence for binding within the pore. Journal of Neurochemistry, 72, 318-326.
19. Farnarier, G., Diop, S., Coulibaly, B., Arborio, S., Dabo, A., Diakite, M., Traore, S., Banou, A., Nimaga, K., Vaz, T. & Doumbo, O. (2000). Onchocercose et épilepsie enquête épidémiologique au Mali. Médecine Tropicale, 60, 151-155.
20. Fischer, P., Kipp, W., Bamuhiga, J., Binta-Kahwa, J., Keifer, A. & Buttner, D. W. (1993). Parasitological and clinical characterization of Simulium neavei-transmitted onchocerciasis in western Uganda. Tropical Medicine and Parasitology, 44, 311-321.
21. Garms, R., Katamanywa, J., Yocha, J. & Rubaale, T. (1996). Effect of vector control and community based distribution of ivermectin on the transmission of Onchocerca volvulus by Simulium neavei in western Uganda. British Simuliid Group Bulletin, 8, 3-5.
22. Gerrits, C. (1983). A West African epilepsy focus. Lancet, i, 358.
23. Giel, R. (1970). The problem of epilepsy in Ethiopia. Tropical and Geographical Medicine, 22, 439-442.
24. Goudsmit, J., van der Waals, F. W. & Gajdusek, D. C. (1983). Epilepsy in the Gbawein and Wroughbarh clan of Grand Bassa county, Liberia: the endemic occurrence of 'see-ee' in the native population. Neuroepidemiology, 2, 24-34.
25. Grunitsky, K. E., Dumas, M., Mbella, E. M., Balogou, A., Belo, M., Hegbe, Y. M. & Ramiandrisoa, H. (1991). Les épilepsies au Togo. Epilepsies, 3, 295-303.
26. Guzzo, C. A., Furtek, C. I., Porras, A. G., Chen, C., Tipping, R., Clineschmidt, C. M., Sciberras, D. G., Hsieh, J. Y. & Lasseter, K. C. (2002). Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. Journal of Clinical Pharmacology, 42, 1122-1133.
27. Horton, J., Witt, C., Ottesen, E. A., Lazdins, J. K., Addiss, D. G., Awadzi, K., Beach, M. J., Belizario, V. Y., Dunyo, S. K., Espinel, M., Gyapong, J. O., Hossain, M., Ismail, M. M., Jayakody, R. L., Lammie, P. J., Makunde, W., Richard-Lenoble, D., Selve, B., Shenoy, R. K., Simonsen, P. E., Wamae, C. N. & Weerasooriya, M. V. (2000). An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology, 121, S147-S160.
28. Jallon, P. (1997). Epilepsy in developing countries. Epilepsia, 38, 1143-1151.
29. Jallon, P. (2002). Epilepsy and epileptic disorders, an epidemiological marker? Contribution of descriptive etiology. Epileptic Disorders, 4, 1-13.
30. Jeliffe, D. B., Jones, P. R. M. & Stroud, C. E. (1962). Nakalanga: notes on the endemic dwarfism of Uganda. Tropical and Geographical Medicine, 14, 97-104.
31. Jilek-Aall, L., Jilek, W. & Miller, J. R. (1979). Clinical and genetic aspects of seizure disorders prevalent in an isolated African population. Epilepsia, 20, 613-622.
32. Kaamugisha, J. & Feksi, A. T. (1988). Determining the prevalence of epilepsy in the semi-urban population of Nakuru, Kenya, comparing two independent methods not apparently used before in epilepsy studies. Neuroepidemiology, 7, 115-121.
33. Kabore, J. K., Cabore, J. W., Melaku, Z., Druet-Cabanac, M. & Preux, P. M. (1996). Epilepsy in a focus of onchocerciasis in Burkina Faso. Lancet, 347, 836.
34. Kaiser, C., Kipp, W., Asaba, G., Mugisa, C., Kabagambe, G., Rating, D. & Leichsenring, M. (1996). The prevalence of epilepsy follows the distribution of onchocerciasis in a west Ugandan focus. Bulletin of the World Health Organization, 74, 361-367.
35. Kaiser, C., Asaba, G., Leichsenring, M. & Kabagambe, G. (1998). High incidence of epilepsy related to onchocerciasis in west Uganda. Epilepsy Research, 30, 247-251.
36. Kaiser, C., Benninger, C., Asaba, G., Mugisa, C., Kabagambe, G., Kipp, W. & Rating, D. (2000). Clinical and electro-clinical classification of epileptic seizures in west Uganda. Bulletin de la Société de Pathologie Exotique, 93, 255-259.
37. Kale, R. (2002). The treatment gap. Epilepsia, 43 (Suppl. 1), 31-33.
38. Kilian, A. H. D. (1994). Onchocerciasis and epilepsy. Lancet, 343, 983.
39. Kim, J. S. & Crichlow, E. C. (1995). Clinical signs of ivermectin toxicity and the efficacy of antigabaergic convulsants as antidotes for ivermectin poisoning in epileptic chickens. Veterinary and Human Toxicology, 37, 122-126.
40. Kipp, W., Burnham, G. & Kamugisha, J. (1992). Improvement in seizures after ivermectin. Lancet, 340, 789-790.
41. Kipp, W., Kasoro, S. & Burnham, G. (1994). Onchocerciasis and epilepsy in Uganda. Lancet, 343, 183-184.
42. Kipp, W., Burnham, G., Bamuhiga, J. & Leichsenring, M. (1996). The Nakalanga syndrome in Kabarole district, western Uganda. American Journal of Tropical Medicine and Hygiene, 54, 80-83.
43. Kohler, P. (2001). The biochemical basis of anthelmintic action and resistance. International Journal for Parasitology, 31, 336-345.
44. Kotsopoulos, I. A. W., van Merode, T., Kessels, F. G. H., de Krom, M. C. T. F. M. & Knottnerus, J. A. (2002). Systematic review and meta-analysis of incidence studies of epilepsy and unproved seizures. Epilepsia, 43, 1402-1409.
45. Leonard, P. J. & Stanfield, J. P. (1965). Some biochemical observations in the Nakalanga. East African Medical Journal, 42, 692-694.
46. Levy, L. F. (1970). Epilepsy in Rhodesia, Zambia and Malawi. African Journal of Medical Sciences, 1, 291-303.
47. Marshall, A. J. & Cherry, J. K. T. (1961). Endocrine dysfunction in a Nakalanga dwarf. Transactions of the Royal Society of Tropical Medicine and Hygiene, 55, 188-191.
48. Mayer, T. W. & Horton, M. L. (1991). Modulation of monomethylhydrazine-induced seizures by ivermectin. Toxicology Letters, 57, 167-173.
49. Newell, E. D., Vyungimana, F. & Bradley, J. E. (1997). Epilepsy, retarded growth and onchocerciasis, in two areas of different endemicity of onchocerciasis in Burundi. Transactions of the Royal Society of Tropical Medicine and Hygiene, 91, 525-527.
50. Oomen, A. P. (1967). Onchocerciasis in the Kaffa province of Ethiopia. Tropical and Geographical Medicine, 19, 231-246.
51. Osuntokun, B. O., Schoenberg, B. S., Nottidge, V. A., Adeuja, A., Kale, O., Adeyefa, A., Bademosi, O., Olumide, A., Oyediran, A. B. O., Pearson, C. A. & Bolis, C. L. (1982). Research protocol for measuring the prevalence of neurologic disorders in developing countries. Neuroepidemiology, 1, 143-153.
52. Osuntokun, B. O., Adeuja, A. O. G., Nottidge, V. A., Bademosi, O., Olumide, A., Ige, O., Yaria, F., Bolis, C. L. & Schoenberg, B. S. (1987). Prevalence of the epilepsies in Nigerian Africans: a community-based study. Epilepsia, 28, 272-279.
53. Ovuga, E., Kipp, W., Mungherera, M. & Kasoro, S. (1992). Epilepsy and retarded growth in a hyperendemic focus of onchocerciasis in rural western Uganda. East African Medical Journal, 69, 554-556.
54. Piraux, A. (1960). Les épilepsies en Afrique Centrale. World Neurology, 1, 510-523.
55. Raper, A. B. & Ladkin, R. G. (1950). Endemic dwarfism in Uganda. East African Medical Journal, 27, 339-359.
56. Rwiza, H. T., Kilonzo, G. P., Haule, J., Matuja, W. B. P., Mteza, I., Mbena, P., Kilima, P. M., Mwaluko, G., Mwang'ombola, R., Mwaijande, F., Rweyemamu, G., Matowo, A. & Jilek-Aall, L. M. (1992). Prevalence and incidence of epilepsy in Ulanga, a rural Tanzanian district: a community-based study. Epilepsia, 33, 1051-1056.
57. Sander, J. W. A. S. & Shorvon, S. D. (1987) Incidence and prevalence studies in epilepsy and their methodological problems: a review. Journal of Neurology, Neurosurgery and Psychiatry, 50, 829-839.
58. Schulz-Key, H., Kläger, S., Awadzi, K., Diallo, S., Greene, B. M., Larivière, M. & Aziz, M. A. (1985). Treatment of human onchocerciasis: the efficacy of ivermectin on the parasite. Tropical Medicine and Parasitology, 36 (Suppl. 2), 20.
59. Schulz-Key, H., Greene, B.M., Awadzi, K., Larivière, M., Kläger, S., Dadzie, Y. & Aziz, M. A. (1986). Efficacy of ivermectin on the reproductivity of female Onchocerca volvulus. Tropical Medicine and Parasitology, 37, 89.
60. Scott, R. A., Lhatoo, S. D. & Sander, J. W. A. S. (2001). The treatment of epilepsy in developing countries: where do we go from here? Bulletin of the World Health Organization, 79, 344-351.
61. Semba, R. D., Murphy, R. P., Newland, H. S., Awadzi, K., Greene, B. M. & Taylor, H. R. (1990). Longitudinal study of lesions of the posterior segment in onchocerciasis. Opthalmology, 97, 1334-1341.
62. Senanayake, N. & Román, G. C. (1993). Epidemiology of epilepsy in developing countries. Bulletin of the World Health Organization, 71, 247-258.
63. Shorvon, S. D. & Farmer, P. J. (1988). Epilepsy in developing countries: a review of epidemiological, sociocultural, and treatment aspects. Epilepsia, 29 (Suppl. 1), S36-S54.
64. Snow, R. W., Williams, R. E. M., Rogers, J. E., Mung'ala, V. O. & Peshu, N. (1994). The prevalence of epilepsy among a rural Kenyan population. Tropical and Geographical Medicine, 46, 175-179.
65. Stanfield, J. P. (1963). Banakalanga. East African Medical Journal, 40, 421-422.
66. Tamai, I. & Tsuji, A. (2000). Transporter-mediated permeation of drugs across the blood-brain barrier. Journal of Pharmaceutical Sciences, 89, 1371-1388.
67. Tekle-Haimanot, R., Abebe, M., Gebre-Mariam, A., Forsgren, L., Heijbel, J., Holmgren, G. & Ekstedt, J. (1990). Community-based study of neurologic disorders in rural central Ethiopia. Neuroepidemiology, 9, 263-277.
68. Turner, M. J. & Schaeffer, J. M. (1999). Mode of action of ivermectin. In Ivermectin and Abamectin, ed. Campbell, W. C. pp. 73-88. New York: Springer-Verlag.
69. Twum-Danso, N. A. Y. (2003). Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. Filaria Journal, 2 (Suppl. 1), S3.